Iovance Biotherapeutics IOVA 深 沪
等待开盘 11-10 09:30:00 美东时间
2.30
-0.010
-0.43%
华盛通- 最 高2.38
- 今 开2.25
- 成交量 2960.37万股
- 最 低 2.08
- 昨 收 2.31
- 总市值 8.33亿
- 52周最高 9.70
- 市盈率 静 --
- 换手率 8.18%
- 52周最低 1.6385
- 委 比 -10.49%
- 总股本 3.62亿
- 历史最高 54.208
- 量 比 0.83
- 振 幅 12.99%
- 历史最低 1.6385
- 每 手 1
- 风险率 2.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
今天 10:22
Earnings Outlook For ARS Pharmaceuticals
ARS Pharmaceuticals (NASDAQ:SPRY) is set to give its latest quarterly earnings ...
11-08 02:04
美股牛股 | Fastly飙升近36%！Q3实现创纪录收入且大幅超预期；BHF涨近27%，获Aquarian溢价私有化
Q3业绩超预期推动股价大涨！FSLY涨近36%、LFST涨近30%；BHF涨近27%，获Aquarian40亿美元私有化>>
11-07 15:08
Iovance Biotherapeutics Reports Positive Earnings Amid Growth
Iovance Biotherapeutics (($IOVA)) has held its Q3 earnings call. Read on for th...
11-07 08:59
Iovance Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results and issued FY25 sales guidance with its midpoint above estimates.
Iovance Biotherapeutics shares are trading higher after the company reported be...
11-06 21:50
Iovance Biotherapeutics Affirms FY2025 Sales Guidance of $250.000M-$300.000M vs $264.918M Est
Iovance Biotherapeutics (NASDAQ:IOVA) affirms FY2025 sales outlook from $250.000 million-$300.000 million to $250.000 million-$300.000 million vs $264.918 million estimate.
11-06 21:01
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Examining the Future: Iovance Biotherapeutics's Earnings Outlook
Iovance Biotherapeutics (NASDAQ:IOVA) is set to give its latest quarterly earni...
11-06 02:02
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $9
HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $20 to $9.
10-30 01:38
